Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Is there a role for angiogenesis inhibition in prostate cancer?

Is there a role for angiogenesis inhibition in prostate cancer? Prostate cancer is the most common male cancer and one of the most common causes of cancer death among men in European countries. In the last years, a large number of new drugs for treatment of castration-resistant prostate cancer (CRPC) have been approved, others are still in an advanced stage of clinical testing. In this review, we provide an overview on new substances which act via modulation or inhibition of angiogenesis. Results and limitations from clinical studies as well as future needs for improvement of those agents in CRPC are critically discussed. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Is there a role for angiogenesis inhibition in prostate cancer?

Download PDF
5 pages

Loading next page...
 
/lp/springer-journals/is-there-a-role-for-angiogenesis-inhibition-in-prostate-cancer-aMuZD56EkT
Publisher
Springer Journals
Copyright
Copyright © 2014 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-014-0187-z
Publisher site
See Article on Publisher Site

Abstract

Prostate cancer is the most common male cancer and one of the most common causes of cancer death among men in European countries. In the last years, a large number of new drugs for treatment of castration-resistant prostate cancer (CRPC) have been approved, others are still in an advanced stage of clinical testing. In this review, we provide an overview on new substances which act via modulation or inhibition of angiogenesis. Results and limitations from clinical studies as well as future needs for improvement of those agents in CRPC are critically discussed.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Nov 28, 2014

References

  • Global burden of cancer: opportunities for prevention
    Jemal, A
  • Evolution of androgen receptor targeted therapy for advanced prostate cancer
    Wong, YN; Ferraldeschi, R; Attard, G; de, BJ
  • EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer
    Mottet, N; Bellmunt, J; Bolla, M; Joniau, S; Mason, M; Matveev, V
  • Novel therapeutic approaches for the treatment of castration-resistant prostate cancer
    Heidegger, I; Massoner, P; Eder, IE; Pircher, A; Pichler, R; Aigner, F
  • Hallmarks of cancer: the next generation
    Hanahan, D; Weinberg, RA
  • Self-regulation of growth in three dimensions
    Folkman, J; Hochberg, M
  • Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond
    Mittal, K; Ebos, J; Rini, B
  • Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis
    Kolch, W; Martiny-Baron, G; Kieser, A; Marme, D
  • Angiogenesis in cancer, vascular, rheumatoid and other disease
    Folkman, J
  • Molecular mechanisms and clinical applications of angiogenesis
    Carmeliet, P; Jain, RK
  • Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer
    Duque, JL; Loughlin, KR; Adam, RM; Kantoff, PW; Zurakowski, D; Freeman, MR
  • Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480
    George, DJ; Halabi, S; Shepard, TF; Vogelzang, NJ; Hayes, DF; Small, EJ
  • Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma
    Gettman, MT; Pacelli, A; Slezak, J; Bergstralh, EJ; Blute, M; Zincke, H
  • Oncogenic functions of IGF1R and INSR in prostate cancer include enhanced tumor growth, cell migration and angiogenesis
    Heidegger, I; Kern, J; Ofer, P; Klocker, H; Massoner, P
  • Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study
    Di, LG; Figg, WD; Fossa, SD; Mirone, V; Autorino, R; Longo, N
  • A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006
    Picus, J; Halabi, S; Kelly, WK; Vogelzang, NJ; Whang, YE; Kaplan, EB
  • Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401
    Kelly, WK; Halabi, S; Carducci, M; George, D; Mahoney, JF; Stadler, WM
  • A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer
    Beardsley, EK; Hotte, SJ; North, S; Ellard, SL; Winquist, E; Kollmannsberger, C
  • A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV
    Steinbild, S; Mross, K; Frost, A; Morant, R; Gillessen, S; Dittrich, C
  • Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer
    Aragon-Ching, JB; Jain, L; Gulley, JL; Arlen, PM; Wright, JJ; Steinberg, SM
  • Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial
    Zurita, AJ; George, DJ; Shore, ND; Liu, G; Wilding, G; Hutson, TE
  • Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer
    Michaelson, MD; Oudard, S; Ou, YC; Sengelov, L; Saad, F; Houede, N
  • Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
    Tannock, IF; Fizazi, K; Ivanov, S; Karlsson, CT; Flechon, A; Skoneczna, I
  • Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer
    Dahut, WL; Gulley, JL; Arlen, PM; Liu, Y; Fedenko, KM; Steinberg, SM
  • Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer
    Ning, YM; Gulley, JL; Arlen, PM; Woo, S; Steinberg, SM; Wright, JJ
  • Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer
    Pili, R; Haggman, M; Stadler, WM; Gingrich, JR; Assikis, VJ; Bjork, A
  • A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer
    Rosen, LS; Hurwitz, HI; Wong, MK; Goldman, J; Mendelson, DS; Figg, WD